Incyte today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal ...
Ooma, Inc. , a smart communications platform for businesses and consumers, today released financial results for the fiscal third quarter ended October 31, 2025. Third Quarter Fiscal 2026 Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback